A Study of Apalutamide in Participants With High‑Risk, Localized or Locally Advanced Prostate Cancer Who Are Candidates for Radical Prostatectomy

Titre officiel

A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of Apalutamide in Subjects With High-risk, Localized or Locally Advanced Prostate Cancer Who Are Candidates for Radical Prostatectomy

Sommaire:

Le but de cette étude est de déterminer si le traitement antiandrogénique combiné à l’apalutamide administré avant et après une prostatectomie radicale chez des participants atteints d’un cancer de la prostate localisé ou localement avancé à risque élevé entraîne une amélioration du taux de réponse pathologique complète (RPC) et une prolongation de la survie sans métastase (SSM) comparativement au traitement antiandrogénique combiné à un placebo.

Description de l'essai

Primary Outcome:

  • Percentage of Participants with Pathologic complete response (pCR)
  • Metastasis-Free Survival (MFS)
Secondary Outcome:
  • Prostate Specific Antigen (PSA)-Free Survival
  • Progression-Free Survival (PFS)
  • Number of Participants with Adverse Events
  • Number of Participants with Laboratory Abnormalities as a Measure of Safety and Tolerability
  • Number of Participants with Treatment Compliance Rate
High-risk prostate cancer accounts for approximately 15 percent (%) of newly diagnosed prostate cancers. A systemic therapy that eradicates micrometastatic disease is needed to improve survival in high-risk participants undergoing radical prostatectomy. It is hypothesized that androgen blockade prior to and after radical prostatectomy may improve outcomes for participants at the highest risk for recurrence. This study is designed to evaluate if androgen blockade administered prior to and after radical prostatectomy will increase the rate of pathological complete response (pCR) and lead to better overall outcomes. ERLEADA (apalutamide, also known as JNJ-56021927 and ARN-509) is an orally available, non-steroidal small molecule, which acts as a potent and selective antagonist of the androgen receptor (AR), currently being developed for the treatment of prostate cancer. The study includes screening phase (approximately up to 35 days before randomization), treatment phase (up to 12 months) and follow-up phase. The end of study (study completion) is defined as last participant assessment at study site with approximate study duration of 8 years. Participants will undergo efficacy, pharmacokinetics and biomarker evaluations. The safety will be monitored throughout the study.

Voir cet essai sur ClinicalTrials.gov

Intéressé(e) par cet essai?

Imprimez cette page et apportez-la chez votre médecin pour discuter de votre admissibilité à cet essai et des options de traitement. Seul votre médecin peut vous recommander pour un essai clinique.

Ressources

Société canadienne du cancer

Ces ressources sont fournies en partenariat avec Société canadienne du cancer